Torrent board approves Scheme of Amalgamation of Curatio Health Care
The scheme is subject to statutory and regulatory approvals as may be necessary.
The scheme is subject to statutory and regulatory approvals as may be necessary.
First PARP inhibitor and new hormonal agent combination approved for these patients in Europe
None of the observations are related to data integrity and management believes that they are addressable
EZHARMIA is the fifth innovative oncology medicine to be launched in Japan by Daiichi Sankyo in the past three years
This combination has the potential to be the first treatment option combining an antibody-drug conjugate plus an immunotherapy in this treatment setting
Post the sale, Patel family has become the single largest promoter shareholder in the company
This is a phase two randomized, double-blind, parallel-group, placebo and active-controlled study
To focus on providing safer burn treatments for women and armed forces
EC grants conditional marketing authorization based on the EFFISAYIL trial
Subscribe To Our Newsletter & Stay Updated